Leukocyte adhesion to endothelium is essential for the development of an appropriate immune-inflammatory response. The viral importance of leukocyte-endothelial adhesive interactions in host defense and homeostasis is illustrated by the clinical manifestations of patients with congenital defects of leukocyte adhesion functions. However, under some circumstances leukocyte adhesion to endothelium may instead lead to vascular and tissue damage. In recent years, there has been remarkable progress in the understanding of the molecular basis of leukocyte adhesion to endothelium, and this knowledge has led to a new approach to immunomodulation in human disease, ie 'antiadhesion' therapy. This review focuses on cell adhesion molecules mediating adhesion of circulating phagocytes to vascular endothelium, on congenital defects of phagocyte adhesion in man, and on the current status of antiadhesion therapy directed towards phagocyte and endothelial adhesion molecules. We will also consider markers of phagocyte activation, which may provide a means to identify those patients who would benefit most from antiadhesion therapy.
CITATION STYLE
Repo, H., & Harlan, J. M. (1999). Mechanisms and consequences of phagocyte adhesion to endothelium. Annals of Medicine. Royal Society of Medicine Press Ltd. https://doi.org/10.3109/07853899909115974
Mendeley helps you to discover research relevant for your work.